Upon joining the study, you will be randomly assigned to receive either depemokimab or placebo. Neither you nor your doctor will know which treatment you are receiving.

The treatment will be administered as an injection under the skin (subcutaneous injection). The placebo is a sterile salt water solution that contains no active medication.

You will continue taking your regular inhaled medications during the study, including your inhaled corticosteroid, long-acting muscarinic receptor antagonist, and long-acting beta2-adrenergic receptor agonist. These are medications that help keep your airways open and reduce inflammation in your lungs.

Throughout the study, you will have access to salbutamol (also known as Novolizer Salbutamol) as a rescue medication.

This medication is an inhalation powder with a dose of 100 micrograms per inhalation.

You should use this medication when you experience sudden breathing difficulties or worsening of your symptoms. It works quickly to open your airways and make breathing easier.

You will attend regular study visits where various assessments will be performed.

During these visits, your breathing function will be tested using a device that measures how much air you can breathe out and how quickly (called spirometry).

Blood samples will be taken to measure the level of certain white blood cells called eosinophils in your blood.

You will be asked to complete questionnaires about your breathing symptoms and quality of life, including the St. George’s Respiratory Questionnaire and the Evaluating Respiratory Symptoms questionnaire.

At Week 52 (approximately one year after starting the study), specific assessments will be performed.

Your responses to the questionnaires about breathing symptoms and quality of life will be compared to your initial responses to measure any changes.

These assessments help determine how the treatment has affected your symptoms and daily functioning over the course of the year.

Throughout the entire study period, any worsening of your condition (called exacerbations) will be recorded.

An exacerbation is when your breathing symptoms suddenly get worse and may require additional treatment, a visit to the emergency department, or hospitalization.

The study will track how often these episodes occur and how severe they are.

The total study duration is expected to continue until the end of 2029.

Your safety will be monitored throughout the study.

Any side effects or health changes you experience will be recorded and evaluated.

You should report any new or worsening symptoms to the study staff during your visits or as instructed.